Sign in
Taking people in United StatesNo phase

Testing a wearable compression device for moderate to severe irritable bowel syndrome

Tests a wearable compression device in adults with moderate to severe irritable bowel syndrome.

Key facts

Who runs it
PGP Health
Where
Bolingbrook, Kissimmee, and Southhaven, United StatesSee the 3 sites
Trial code
Registry title
A Prospective Trial of a Variable Compression System for Moderate to Severe Irritable Bowel Syndrome
Status
Recruiting
People taking part
20 people, planned
Started
21 May 2025
Planned end
1 May 2026
Type of study
Interventional
Treatments tested
  • Variable Compression System
Record updated
29 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with moderate to severe irritable bowel syndrome (IBS). They will wear a compression device for at least 6 hours a day.

Age
18 Years to 60 Years
Sex
All sexes can join.
Disease stage
Moderate to severe IBS, diagnosed by the Rome Criteria. This can be the constipation type (IBS-C), the diarrhea type (IBS-D) or the mixed type (IBS-M).
Earlier treatment
People who took part in another trial of an investigational drug within 30 days before screening cannot join.
Biomarker or test result
Weight of ≥50 kg (110 lb) and a body mass index between 18 and 40 kg/m2.

Main reasons for not taking part

  • Allergy to the device or its parts, or serious allergies (mild seasonal allergies are allowed)
  • Hospital stay or major surgery within 30 days before screening
  • Being pregnant or having a positive urine pregnancy test
  • Drug or alcohol use disorder
  • End-stage organ disease, or other serious illnesses that would make the trial hard or unsafe

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Written informed consent to participate in the trial as prescribed
  • Subjects with a weight of ≥50 kg and a body mass index between 18 and 40 kg/m2
  • Diagnosed with IBS(C)-constipation, IBS(D)-diarrhea, or IBS(M)-mixed patients' diagnosis according to Rome Criteria (moderate to severe)

Who cannot take part

  • Allergy to the investigational device or any components or clinically significant allergies (excluding mild seasonal allergies), in the opinion of the investigator
  • Hospital admission or major surgery within 30 days prior to screening
  • Participation in any other investigational drug trial within 30 days prior to screening
  • Clinically relevant history of gastrointestinal, cardiovascular, musculoskeletal, endocrine, hematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic, immunologic, lipid metabolism disorders, or psychiatric disorders making implementation of the protocol or interpretation of the trial results difficult, or that would put the participant at risk by participating in the trial in the opinion of the Investigator
  • Participant with substance use disorder (SUD) and/or alcohol use disorder (AUD)
  • Participant who has other conditions that may affect compliance in the opinion of the investigator, or who are unable to participate in the trial on his/her own
  • Participant with end stage organ disease
  • Pregnant, or positive urine pregnancy test

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 60 years old?

Where in United States

  • UChicago Medicine AdventHealth Medical Group Gastroenterology at BolingbrookBolingbrook, United StatesContact: Hadi Saddiqui, DO, MPH (principal investigator)Taking people
  • Central Florida Gastro ResearchKissimmee, United StatesContact: Muhammad Mohiuddin, MD (principal investigator)Taking people
  • Delta Gastroenterology PCSouthhaven, United StatesContact: Ulric Duncan, MD (principal investigator)Taking people

About the trial

What the trial wants to find out

This prospective, interventional trial is intended to determine the safety and effectiveness of the Variable Compression System (VCS) device for Irritable Bowel Syndrome (IBS). This pilot study will enroll 20 subjects who will be required to wear the VCS device for a minimum of 6 hours a day and follow up at 21 days, 8 weeks, and 6 months post-device administration.

The group in the trial

  • Pilot VCS CohortTreatment being tested

    Wear VCS device for 6+ hours per day

    Treatment: Variable Compression System

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Prospective Interventional Trial With a Non-invasive Variable Compression System (VCS) to Determine the Efficacy in Patients With Moderate to Severe Irritable Bowel Syndrome (IBS)
Plain-language title
Testing a wearable compression device for moderate to severe irritable bowel syndromeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT07540312, who can take part
Record updated
29 April 2026